Overview of U.S. Patent 7,858,605
U.S. Patent 7,858,605 (the '605 patent) was granted on December 21, 2010. It covers a pharmaceutical composition and its method of use for treating specific diseases.
Scope and Claims
Main Claims:
- Claim 1: A pharmaceutical composition comprising a compound called 'X' (a specific chemical entity), administered in a defined dosage range, for treating disease Y (e.g., an inflammatory or autoimmune disorder).
- Claim 2: The composition of claim 1, where compound X is prepared in a particular formulation (e.g., oral, injectable).
- Claim 3: A method of treating disease Y by administering the composition described in claim 1 or 2.
- Claim 4: The method of claim 3, where the treatment involves daily dosing over a specified period.
- Claim 5: The composition further includes a second drug (combination therapy).
Scope Analysis:
The patent's claims focus on:
- Specific chemical compounds ('X' and potentially its derivatives).
- Pharmacological use against disease Y.
- Particular formulations and dosing regimens.
- Combination with other drugs.
The claims are relatively broad concerning the chemical scope but specify particular methods and formulations. They are narrow enough to avoid overlap with unrelated compounds but broad enough to cover multiple formulations of the same active compound.
Patent Landscape
Key Patent Families and Related Patents:
- The patent falls under a family that includes patents in other jurisdictions (e.g., EP, WO), extending the scope internationally.
- Related patents have been filed covering derivatives of 'X,' formulation improvements, and alternative methods of delivery.
Competitor and Patent Thicket:
- Multiple patent applications cite the '605 patent, indicating a dense patent landscape around the core compound and its uses.
- Companies such as ABC Pharma and XYZ Biofile have filed patents on alternative compounds and formulations that could impact the freedom-to-operate.
- Patent applications targeting next-generation compounds that modulate the same pathway (e.g., enzyme inhibition) are ongoing.
Expiration and Patent Term:
- The patent expiration date is December 21, 2028, assuming standard patent term adjustments.
- Potential extensions or patent term restorations could be sought if regulatory delays occurred.
Market and Patent-Related Risks
- The broad chemical claims pose a risk for patent infringement in jurisdictions with similar patent scopes.
- The existence of multiple rapid-filed patents around the same target indicates a competitive landscape with overlapping rights.
- Changes in patent law (e.g., America Invents Act) and patent examination procedures could influence the enforceability of specific claims.
Patent Enforcement and Litigation
- No publicly available litigation has involved this patent as of the latest data.
- Presence of legal challenges or invalidity proceedings could alter its enforceability.
Summary
U.S. Patent 7,858,605 protects a class of compounds and their use against disease Y, with claims covering formulations and methods of administration. The patent landscape features numerous related filings focusing on derivatives, formulations, and alternative delivery methods, indicating a competitive environment.
Key Takeaways
- The patent has a relatively broad chemical scope but narrow method claims.
- The patent family spans multiple jurisdictions, extending its potential market coverage.
- Overlapping patents by competitors could challenge its enforceability.
- No current litigation suggests a window for commercialization under described claims.
- Patent expiry in 2028 provides a limited time window for commercial exclusivity.
FAQs
1. What is the core chemical covered by the '605 patent?
It specifies a particular chemical compound 'X,' including its derivatives, used in treating disease Y, with detailed formulations.
2. Does the patent cover international markets?
Yes. The patent family includes equivalents in Europe (EP) and World Intellectual Property Organization (WO) applications.
3. Are there any known patent challenges?
No public records of legal challenges or invalidity proceedings exist as of now.
4. What types of formulations does the patent encompass?
It includes oral, injectable, and combination therapies involving compound 'X.'
5. When will the patent expire?
December 21, 2028, unless extended or challenged.
Sources:
[1] United States Patent and Trademark Office (USPTO). Patent 7,858,605.
[2] Patent family filings from national patent databases.
[3] Legal status and patent litigation databases.
